Phillipp D. Le Coutre

Author

Charité - Universitätsmedizin Berlin

Also Known As

P D Le Coutre, P D le Coutre, P de Coutre, P. D. le Coutre, Phillipp D. Le Coutre

Publications

429

Citations

H-Index

Concepts

All Affiliations

Charité - Universitätsmedizin Berlin The University of Texas MD Anderson Cancer Center Jena University Hospital Ollscoil na Gaillimhe – University of Galway University of Bologna

About

Phillipp D. Le Coutre is an author at Charité - Universitätsmedizin Berlin specializing in medicine, oncology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	361
2	Molecular Medicine	3	3	63
3	Health Sciences	2	2	53
4	Immunology	2	2	75
5	Cell Biology	1	1	65

Phillipp D. Le Coutre

Publications

409

Citations

H-Index

Page 1

	Year	Citations
Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib T D Kim, Delphine Réa, Michaela Schwarz, Leukemia Hematological MalignancyCardiovascular DiseaseHematologyPathologyMedicine	2013	233
MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia Francis J. Giles, Ronan Swords, Arnon Nagler, Leukemia Bcr–abl InhibitorTumor BiologyHematological MalignancyAurora KinaseMedicine	2012	65
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily Timothy P. Hughes, Andreas Hochhaus, Hagop M. Kantarjian, Haematologica	2014	48
Comparison of nilotinib and imatinib in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): ENESTnd beyond one year. Richard A. Larson, Phillipp D. Le Coutre, Josy Reiffers, Journal of Clinical Oncology PharmacotherapyMyeloid NeoplasiaChronic PhaseHematological MalignancyNilotinib 300	2010	38
Bosutinib vs imatinib for newly diagnosed chronic myeloid leukemia in the BFORE trial: 24-month follow-up. Jörge E. Cortes, Michael J. Mauro, Michael W. Deininger, Journal of Clinical Oncology Hematological MalignancyChronic Myeloid LeukemiaImatinib ArmOncologyMetronomic Therapy	2018	15
Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib. Frank Giles, Hagop M. Kantarjian, Phillipp D. Le Coutre, Journal of Clinical Oncology Hematological MalignancyChronic Myeloid LeukemiaOncologyPhase Ii 2101Median Duration	2010	10

Page 1